Daré Bioscience, Inc. (DARE)
NASDAQ: DARE · Real-Time Price · USD
1.530
-0.040 (-2.55%)
At close: Mar 6, 2026, 4:00 PM EST
1.530
0.00 (0.01%)
After-hours: Mar 6, 2026, 7:35 PM EST
Daré Bioscience Employees
As of December 31, 2024, Daré Bioscience had 23 total employees, including 21 full-time and 2 part-time employees. The number of employees decreased by 3 or -11.54% compared to the previous year.
Employees
23
Change (1Y)
-3
Growth (1Y)
-11.54%
Revenue / Employee
n/a
Profits / Employee
-$759,302
Market Cap
21.86M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| IO Biotech | 78 |
| Vistagen Therapeutics | 59 |
| Senti Biosciences | 34 |
| Citius Pharmaceuticals | 23 |
| Skye Bioscience | 16 |
| Reviva Pharmaceuticals Holdings | 14 |
| Genenta Science | 13 |
| Neuphoria Therapeutics | 8 |
DARE News
- 12 days ago - Daré Bioscience Announces FDA Clearance of IND for Phase 2 Clinical Study of DARE-HPV, a Potential Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer - GlobeNewsWire
- 3 months ago - DARE to PLAY™ Sildenafil Cream Now Available for Pre-Order by Prescription: First Evidence-Based Topical Arousal Cream for Women Begins Commercial Rollout in Select States via 503B Outsourcing Facility - GlobeNewsWire
- 3 months ago - Daré Bioscience, Inc. (DARE) Discusses DARE to PLAY Sildenafil Cream as a Treatment Option for Female Genital Arousal Concerns Transcript - Seeking Alpha
- 4 months ago - Daré Bioscience, Inc. (DARE) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 months ago - Daré Bioscience Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 4 months ago - Daré Bioscience to Host Third Quarter 2025 Financial Results and Company Update Conference Call and Webcast on November 13, 2025 - GlobeNewsWire
- 5 months ago - Daré Bioscience to Receive up to $499,000 to Support Preeclampsia Research - GlobeNewsWire
- 7 months ago - Daré Bioscience, Inc. (DARE) Q2 2025 Earnings Call Transcript - Seeking Alpha